Alpha Tau Medical shares were under pressure after the company said it has completed patient enrollment in its multicenter IMPACT pilot study evaluating its Alpha DaRT alpha-radiation therapy with first-line chemotherapy for newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. The update comes ahead of follow-up and data maturation, with initial results expected in early 2027, a key milestone that management said will inform the design of a planned pivotal trial.
DRTS shares closed Monday at $14.11, down 3.62%, after enrollment in the study expanded to 48 patients from an initial 12, reflecting “strong demand” from both patients and clinicians. The stock traded between $3.35 and $15.10 over the past year.
Key takeaways
- Price move: Alpha Tau Medical shares closed at $14.11 on Monday, down 3.62%.
- Catalyst: The company completed patient enrollment in its multicenter IMPACT study, expanding enrollment threefold to 48 patients.
- Clinical focus: Alpha DaRT is being tested as a one-time intratumoral addition alongside standard first-line chemotherapy for advanced pancreatic cancer.
- Next milestone: Initial results are expected in early 2027 to support the design of a planned pivotal study.
- Implication: Investors will now look for data readouts that could validate safety and effectiveness signals and sharpen expectations for a larger, potentially registrational trial.
What the IMPACT enrollment completion means
Alpha Tau said the multicenter IMPACT study has finished enrolling patients for its pilot evaluation of Alpha DaRT in combination with first-line chemotherapy in people with unresectable locally advanced or metastatic pancreatic adenocarcinoma. Enrollment expanded three times during the trial, increasing from the original 12 patients to 48 participants.
Management framed the enrollment growth as evidence of strong interest in the therapy. The company’s broader strategy positions Alpha DaRT as a potential new treatment option for a disease where most patients are not candidates for surgery at diagnosis and outcomes under systemic chemotherapy can be limited.
How Alpha DaRT fits into standard care
Alpha DaRT is an alpha-radiation therapy delivered as a one-time intratumoral addition alongside standard chemotherapy regimens, including mFOLFIRINOX or gemcitabine plus nab-paclitaxel (Abraxane). The company said the approach is supported by a favorable safety profile observed in earlier Israeli and Canadian studies.
The IMPACT pilot study builds on first-in-human Alpha DaRT trials conducted at Hadassah Medical Center in Jerusalem and at Canadian institutions. Results from those earlier studies were presented at major medical conferences, including the 2026 ASCO Gastrointestinal Cancers Symposium, Digestive Disease Week, and the ASCO Annual Meeting.
Market reaction and what investors will watch next
While the enrollment completion is a meaningful operational milestone, it did not translate into a higher close for DRTS on Monday. The stock fell 3.62% to $14.11, and in pre-market trading was indicated slightly higher at $14.45, up 2.41%.
In clinical-development timelines, “enrollment complete” updates often reduce uncertainty about trial execution, but the market tends to focus quickly on the next data catalyst. Here, Alpha Tau indicated that the program is now moving into follow-up and data maturation, with initial results expected in early 2027. Those findings are intended to inform the design of a planned pivotal study, which investors will likely view as the more decisive step for potential regulatory and commercial positioning.
Bigger picture: a multi-trial pancreatic cancer roadmap
The IMPACT program is part of Alpha Tau’s wider pancreatic cancer portfolio. The company also highlighted the ACAPELLA trial in France and a study at the University of Verona, framing these efforts as components of a broader global development strategy for Alpha DaRT.
Pancreatic cancer remains among the most lethal cancers, and for many patients—particularly those diagnosed with locally advanced or metastatic disease—systemic chemotherapy is the mainstay of treatment. Against that backdrop, Alpha Tau’s strategy centers on adding a targeted radiation component directly within tumors while pairing it with standard chemotherapy regimens.
As the company completes enrollment and enters follow-up, the near-term focus shifts to ongoing monitoring of patient outcomes and the production of the early 2027 data set. Investors will likely be watching for updates on follow-up timelines, the pace of data maturation, and any additional trial design details that emerge as management prepares the groundwork for a pivotal study.
